RCM
RIGL icon

Rotella Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Rotella Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,976
Closed -$120K – 194
2015
Q4 		$120K Sell
3,976
-2,306
-37% -$69.9K 0.11% 288
2015
Q3 		$155K Buy
6,282
+5,196
+478% +$155K 0.05% 358
2015
Q2 		$35K Buy
1,086
+10
+0.9% +$382 0.03% 394
2015
Q1 		$38K Buy
+1,076
New +$29.5K 0.03% 470

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Rotella Capital Management's RIGL Position: Q1 2016 in Review

Rotella Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q1 2016, closing a stake of 3,976 shares — an estimated $120K sold.

Rotella Capital Management first reported a position in RIGL in Q1 2015 and held it in 4 quarters. The position peaked at $155K in Q3 2015. 120 funds tracked by Wall St. Rank hold RIGL as of Q1 2016.

  • Rotella Capital Management reported no remaining Rigel Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Rotella Capital Management sold 3,976 Rigel Pharmaceuticals shares in Q1 2016, an estimated $120K.
  • Rotella Capital Management first reported a position in Rigel Pharmaceuticals in Q1 2015 and held it in 4 quarters.
  • Rotella Capital Management's Rigel Pharmaceuticals position peaked at $155K in Q3 2015.
  • 120 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2016.

Based on Rotella Capital Management's 13F filing for Q1 2016, filed 13 May 2016.